OakChart

Atea Pharmaceuticals Inc

AVIRHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 1:52 PM ET

4.23+0.03 (0.70%)
2026-11-11 19:53 CET
Market cap
336.86 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-155.40 USD m
Free cash flow, TTM
-140.57 USD m
EPS diluted, TTM
-1.96
P/E
-
Compare

Price

AVIR against its 20, 50 and 200-day averages
2050200earnings
4.004.505.005.506.00696K1.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AVIRclose 4.2320-day 4.2550-day 4.85200-day 4.954.23

34.4% under the 52-week high of 6.45 on 10 Mar 2026. 52-week low 2.87 on 13 Nov 2025. Last 15 sessions, 14.5% high to low

Profile

AVIR
52-week range, 38% of the way up
2.876.45

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

IndexRUT
Employees55
IPOOct 30, 2020
Beta0.71
ATR, 14d0.25
Rel volume0.77
Short float4.72%
Insider own20.46%
Inst own71.68%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap339.65M
Enterprise Value148.66M
Income-155.40M
Sales0.00M
Book/sh2.19
Cash/sh2.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees55
IPOOct 30, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.93
P/C1.78
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.00
Current Ratio8.00
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.96
EPS next Y-1.40
EPS next Q-0.55
EPS this Y1.80%
EPS next Y26.51%
EPS next 5Y11.93%
EPS past 3/5Y-11.75% -71.02%
Sales past 3/5Y- -
EPS Y/Y TTM-10.43%
Sales Y/Y TTM-
EPS Q/Q24.63%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.20.79% -

Ownership

Insider Own20.46%
Insider Trans0.04%
Inst Own71.68%
Inst Trans-0.02%
ROA-57.17%
ROE-63.24%
ROIC-88.46%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.48%
SMA50-12.88%
SMA200-14.57%
Trades-

Technical

Shs Outstand80.30M
Shs Float63.79M
Short Float4.72%
Short Ratio10.60
Short Interest3.01M
52W High6.45 -34.43%
52W Low2.87 47.37%
Volatility5.86% 6.02%
ATR (14)0.25
RSI (14)42.70
Beta0.71
Rel Volume0.77
Avg Volume283.72K
Volume150,447

Performance

Perf Week-5.17%
Perf Month-15.07%
Perf Quarter-16.58%
Perf Half Y-7.45%
Perf YTD18.47%
Perf Year25.13%
Perf 3Y45.84%
Perf 5Y-60.25%
Perf 10Y-
Recom1.67
Target Price8.50
Prev Close4.20
Price4.23
Change %0.70%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Aug 13, 2024UpgradeMMorgan StanleyUnderweight → Equal-Weight$2 → $6.88+62.7%
Aug 10, 2023DowngradeJJP MorganNeutral → Underweight
Jan 06, 2022DowngradeMMorgan StanleyEqual-Weight → Underweight$14 → $7+65.5%
Nov 18, 2021DowngradeSSVB LeerinkOutperform → Mkt Perform
Oct 20, 2021DowngradeJJP MorganOverweight → Neutral$61 → $16+278.3%
Oct 05, 2021DowngradeMMorgan StanleyOverweight → Equal-Weight$55+1,200.4%
Nov 25, 2020InitiatedEEvercore ISIOutperform
Nov 24, 2020InitiatedWWilliam BlairOutperform$60+1,318.6%
Nov 24, 2020InitiatedMMorgan StanleyOverweight$49+1,058.5%
Nov 24, 2020InitiatedJJP MorganOverweight$45+964.0%

Peers

Mkt cap
TickerCompanyMkt cap
ENTAEnanta Pharmaceuticals Inc339.02M
ASMBAssembly Biosciences Inc456.99M
ABUSArbutus Biopharma Corp763.69M
VIRVir Biotechnology Inc2.25B
ALGSAligos Therapeutics Inc15.33M
COCPCocrystal Pharma Inc19.65M
IVVDInvivyd Inc176.06M
TRAWTraws Pharma Inc3.77M
AIMAIM ImmunoTech Inc6.13M
SNGXSoligenix Inc7.52M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lucidi BrunoDirectorJun 18 '26Option Exercise0.0029,6000142,350Jun 23 05:00 PM
BERGER FRANKLIN MDirectorJun 18 '26Option Exercise0.0029,6000536,097Jun 23 05:00 PM
DUNCAN BARBARA GAYLEDirectorJun 18 '26Option Exercise0.0029,600092,350Jun 23 05:00 PM
Polsky BruceDirectorJun 18 '26Option Exercise0.0029,6000124,806Jun 23 05:00 PM
Murphy Polly A.DirectorJun 18 '26Option Exercise0.0029,6000121,745Jun 23 05:00 PM
Adams Jerome M.DirectorJun 18 '26Option Exercise0.0029,600092,350Jun 23 05:00 PM
Corcoran AndreaSee RemarksMar 11 '26Option Exercise1.2460,00074,400823,576Mar 13 06:00 PM
Sommadossi Jean-PierrePresident, CEO, and ChairmanFeb 03 '26Option Exercise1.24300,000372,000767,830Feb 03 07:46 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFMCU.S. Micro Cap Portfolio ETF Class Shares-
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Atea Beats On A Narrower Loss, But Hercules Debt Deal And Slipping Timelines Define The Quarter (Earnings Whispers)
  • Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital (GlobeNewswire)
  • Atea's Phase 3 Win Meets A Sliding Stock As Cash And C-Forward Timing Take Focus (Earnings Whispers)
  • Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026 (GlobeNewswire)
  • Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
  • Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 (GlobeNewswire)
  • FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimers data (BioPharma Dive)
  • Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus (GlobeNewswire) -6.43%
  • Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus (GlobeNewswire)
  • Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
  • Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 (GlobeNewswire)
  • Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline (GlobeNewswire) -16.91%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.400-0.505-0.3700.000.002
2026Q22026-08-12-0.410-0.555-0.4110.000.002
2026Q12026-05-12-0.570-0.555-0.5740.000.002
2025Q42026-03-05-0.570-0.485-0.5740.000.002
2025Q32025-11-12-0.530-0.415-0.5320.000.002
2025Q22025-08-07-0.440-0.415-0.4440.000.002
2025Q12025-05-12-0.400-0.503-0.4020.000.003
2024Q42025-03-06-0.400-0.289-0.3970.000.003
2024Q32024-11-07-0.370-0.427-0.3690.000.003
2024Q22024-08-07-0.480-0.663-0.4810.000.004
2024Q12024-05-14-0.750-0.521-0.7530.000.004
2023Q42024-02-28-0.470-0.432-0.4690.000.004
2023Q32023-11-08-0.400-0.462-0.3970.000.004
2023Q22023-08-08-0.340-0.470-0.3380.000.004
2023Q12023-05-08-0.430-0.476-0.4260.000.004
2022Q42023-02-28-0.410-0.444-0.4130.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.5091.717-0.13348.62163
2021FY1.3700.4521.373351.37258.98
2022FY-1.390-1.309-1.3920.000.00
2023FY-1.630-1.408-1.6300.000.00
2024FY-2.000-1.804-1.9980.000.00
2025FY-1.940-1.725-2.0000.000.00
2026FY--1.905--0.00
2027FY--1.400--30.00
2028FY--1.325--72.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-101000.000.000.00
2026Q4S2026-11-091000.000.000.00
2026Q4S2026-08-131000.000.000.00
2026Q4S2026-05-131000.000.000.00
2026Q4S2026-03-061000.000.000.00
2026Q4S2025-11-131000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4E2026-11-10210-0.55-0.72-0.38
2026Q4E2026-11-09200-0.57-0.72-0.42
2026Q4E2026-10-27200-0.57-0.72-0.42
2026Q4E2026-08-13211-0.57-0.72-0.42
2026Q4E2026-07-29200-0.50-0.54-0.45

Estimate history

EPS, annual-0.11-0.17-0.1331.373-1.392-1.63-1.998-1.943-1.9603
Period20182019202020212022202320242025TTM
EPS, quarterly-0.369-0.397-0.402-0.444-0.532-0.574-0.574-0.411-0.401
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0048.633351.36700000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual82.61782.61782.43783.10383.28883.43684.46378.12780.295
Period20182019202020212022202320242025MRQ
Shares, quarterly84.46384.46385.57981.13778.12778.12780.02780.20580.295
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.00351.3748.630.000.00
Cost of Goods Sold Incl. D&A0.420.420.420.420.260.030.020.020.02
Gross Profit-0.42-0.42-0.42-0.42-0.26351.3448.61-0.02-0.02
Selling, General and Administrative Excl. Other171.64180.47192.53163.75130.39212.9659.6414.599.46
Research and Development144.19148.02144.10114.2481.94167.2138.0210.176.67
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-172.05-180.89-192.95-164.16-130.65138.38-11.03-14.61-9.48
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.000.00
Net Income Before Taxes-162.06-164.51-167.46-134.94-119.50138.59-10.95-14.03-9.06
Income Taxes-6.66-6.160.931.02-3.5917.400.000.000.00
Consolidated Net Income-155.40-158.35-168.38-135.96-115.91121.19-10.95-14.03-9.06
Net Income From Continuing Operations-155.40-158.35-168.38-135.96-115.91121.19-10.95-14.03-9.06
Net Income-155.40-158.35-168.38-135.96-115.91121.19-10.95-14.03-9.06
EPS (Recurring)-1.94-1.94-2.00-1.63-1.391.37-0.13-0.17-0.11
EPS (Basic, Before Extraordinaries)-1.96-1.94-2.00-1.63-1.391.46-0.13-0.17-0.11
EPS (Diluted)-1.96-1.94-2.00-1.63-1.391.37-0.13-0.17-0.11
EBITDA-171.64-180.47-192.53-163.75-130.39138.41-11.01-14.59-9.46
Non-Operating Income (Expense)10.0016.3825.4929.2211.150.210.080.570.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.9816.3740.9039.0536.9128.925.440.620.41
Price To Earnings Ratio----13.156.54---
Price To Sales Ratio-----2.2570.82--
Gross Margin-----99.9999.96--
Operating Margin-----39.38-22.68--
Net Margin-----34.49-22.51--
Shares Outstanding80.3078.1384.4683.4483.2983.1082.4482.6282.62
Market Capitalization336.86336.86282.95254.48400.61742.943,451.733,445.95-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.100.100.100.100.100.100.10
Gross Profit-0.10-0.10-0.10-0.10-0.10-0.10-0.10-0.10
Selling, General and Administrative Excl. Other33.9134.9947.9054.8345.4641.2438.9438.92
Research and Development27.0928.1541.1347.8238.3532.2729.5825.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.01-35.10-48.01-54.93-45.57-41.34-39.04-39.03
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-32.12-32.91-45.39-51.63-41.85-36.95-34.07-33.32
Income Taxes0.040.020.05-6.770.200.210.200.23
Consolidated Net Income-32.16-32.93-45.44-44.87-42.05-37.16-34.27-33.54
Net Income From Continuing Operations-32.16-32.93-45.44-44.87-42.05-37.16-34.27-33.54
Net Income-32.16-32.93-45.44-44.87-42.05-37.16-34.27-33.54
EPS (Recurring)-0.40-0.41-0.57-0.57-0.53-0.44-0.40-0.40
EPS (Basic, Before Extraordinaries)-0.40-0.41-0.57-0.57-0.53-0.44-0.40-0.40
EPS (Diluted)-0.40-0.41-0.57-0.57-0.53-0.44-0.40-0.40
EBITDA-33.91-34.99-47.90-54.83-45.46-41.24-38.94-38.92
Non-Operating Income (Expense)1.892.192.623.303.714.394.975.71
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.742.672.953.623.573.695.4911.29
Shares Outstanding80.3080.2080.0378.1378.1381.1485.5884.46
Market Capitalization336.86372.13428.64278.91230.14308.09255.72282.95

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments301.83454.72578.11646.71764.38850.1221.6634.49
Short Term Receivables0.000.000.000.000.005.820.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets9.167.6312.3514.218.037.540.250.21
Total Current Assets310.99462.36590.46660.92772.40863.4821.9134.70
Net Property, Plant & Equipment1.092.123.124.090.180.050.040.06
Total Investments and Advances0.000.000.000.200.300.110.110.11
Intangible Assets-0.000.000.000.000.00-0.00
Other Assets3.140.201.401.490.000.000.010.00
Total Assets315.22464.67594.97666.71772.89863.6322.0734.86
Short Term Debt Incl. Current Port. of LT Debt0.840.800.760.720.200.000.000.00
Accounts Payable12.954.464.252.554.530.060.550.39
Income Tax Payable--0.000.102.57---
Other Current Liabilities26.0013.3527.3615.1149.58315.741.891.37
Total Current Liabilities39.7818.6032.3818.4856.88315.802.441.76
Long Term Debt0.000.841.642.400.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.006.365.765.255.930.040.100.15
Total Liabilities39.7825.8039.7826.1462.81315.832.531.91
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0069.1169.11
Common Equity275.43438.87555.19640.57710.08547.80-49.57-36.16
Total Shareholders Equity275.43438.87555.19640.57710.08547.8019.5432.95
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity275.43438.87555.19640.57710.08547.8019.5432.95
Total Liabilities & Stockholders Equity315.22464.67594.97666.71772.89863.6322.0734.86
Book Value Per Share3.535.206.657.698.546.65-0.60-0.44
Tangible Book Value Per Share3.535.206.657.698.546.65-0.60-0.44
Full-Time Employees555675705939--
Price to Book Ratio1.920.620.440.601.056.29-45.04-
Return on Assets-40.61-31.78-21.55-16.1014.81-2.47-49.30-
Return on Equity-44.34-33.88-22.74-17.1619.27-3.86-53.47-
Return on Invested Capital-57.49-38.29-24.42-18.0317.07-2.00-71.81-27.51
Quick Ratio7.8224.8518.2435.7713.582.739.0019.71
Current Ratio7.8224.8518.2435.7713.582.739.0019.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-155.40-158.35-168.38-135.96-115.91121.19-10.95-14.03-9.06
Depreciation0.420.420.420.420.260.030.020.020.02
Other Funds (Non Cash)6.499.4239.9533.9841.2539.627.460.620.41
Funds from Operations-148.50-148.51-128.02-101.56-74.40160.84-3.47-13.39-8.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital7.9316.48-7.4816.16-46.59-247.84300.200.580.72
Cash from Operating Activities-140.57-132.03-135.50-85.39-120.98-87.00296.73-12.81-7.91
Capital Expenditures0.000.000.000.00-1.94-0.00-0.03-0.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments160.70188.7956.1040.30-453.470.000.000.000.00
Purchase of Investments-164.12-281.94-461.18-562.36-545.350.000.000.000.00
Sale Or Maturity of Investments324.81470.73517.28602.6691.890.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities160.70188.7956.1040.30-455.41-0.00-0.03-0.00-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.20-25.260.270.260.371.47531.75-0.0127.48
Repurchase of Common Pref Stock0.00-25.520.000.000.000.000.000.000.00
Sale of Common Pref Stock1.200.260.270.260.371.47531.75-0.0127.48
Proceedsfrom Stock Options0.250.200.270.260.140.00531.72-0.0127.48
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.75-0.480.000.000.000.000.000.000.00
Other Financing Activities Uses-0.75-0.480.000.000.000.000.000.000.00
Cash from Financing Activities0.45-25.750.270.260.371.47531.75-0.0127.48
Net Change in Cash20.5831.02-79.13-44.84-576.02-85.54828.46-12.8319.56
Free Cash Flow-140.57-132.03-135.50-85.39-122.92-87.01296.71-12.82-7.92
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow------11.61--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments191.20219.47256.01301.83329.31379.71
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets9.079.207.199.166.835.89
Total Current Assets200.27228.66263.20310.99336.14385.60
Net Property, Plant & Equipment0.310.570.831.091.351.61
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.00-0.000.00
Other Assets0.133.053.053.145.474.39
Total Assets200.71232.28267.08315.22342.96391.61
Short Term Debt Incl. Current Port. of LT Debt0.210.420.630.840.830.82
Accounts Payable4.8410.069.4512.953.528.84
Other Current Liabilities19.9717.6423.2926.0015.8310.45
Total Current Liabilities25.0228.1233.3739.7820.1820.12
Long Term Debt0.000.000.000.000.210.42
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.006.796.64
Total Liabilities25.0228.1233.3739.7827.1827.19
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity175.68204.16233.71275.43315.78364.42
Total Shareholders Equity175.68204.16233.71275.43315.78364.42
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity175.68204.16233.71275.43315.78364.42
Total Liabilities & Stockholders Equity200.71232.28267.08315.22342.96391.61
Book Value Per Share2.192.552.923.534.044.49
Tangible Book Value Per Share2.192.552.923.534.044.49
Full-Time Employees---55--
Price to Book Ratio1.921.591.530.880.650.75
Return on Assets-57.17-52.99-47.95-40.61-35.26-30.18
Return on Equity-63.24-58.14-52.58-44.34-37.98-32.38
Return on Invested Capital-18.31-16.13-19.44-16.29-13.31-10.19
Quick Ratio8.008.137.897.8216.6619.17
Current Ratio8.008.137.897.8216.6619.17

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-32.16-32.93-45.44-44.87-42.05-37.16
Depreciation0.100.100.100.100.100.10
Other Funds (Non Cash)3.082.843.15-2.583.443.35
Funds from Operations-28.98-29.99-42.19-47.34-38.50-33.71
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.11-7.09-4.2019.12-1.870.84
Cash from Operating Activities-28.87-37.08-46.39-28.22-40.38-32.87
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments50.0534.3129.7446.5941.3015.29
Purchase of Investments-11.97-33.81-74.55-43.79-14.78-100.73
Sale Or Maturity of Investments62.0268.12104.2890.3856.08116.02
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities50.0534.3129.7446.5941.3015.29
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.200.001.000.00-11.30-14.09
Repurchase of Common Pref Stock0.000.000.000.00-11.43-14.09
Sale of Common Pref Stock0.200.001.000.000.120.00
Proceedsfrom Stock Options0.120.000.130.000.060.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.750.000.000.00
Other Financing Activities Uses0.000.00-0.750.000.000.00
Cash from Financing Activities0.200.000.260.00-11.30-14.09
Net Change in Cash21.37-2.77-16.4018.37-10.38-31.67
Free Cash Flow-28.87-37.08-46.39-28.22-40.38-32.87

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.72%3.0M63.8M283.19K
2026-10-154.81%3.1M63.8M299.75K
2026-09-3012.36%7.9M63.8M308.61K
2026-09-1511.96%7.6M63.8M329.14K
2026-08-3112.01%7.7M63.8M322.22K
2026-08-1412.03%7.7M63.8M346.75K
2026-07-3111.89%7.5M63.3M360.80K
2026-07-1512.25%7.8M63.3M332.32K
2026-06-3011.04%7.0M63.3M332.97K
2026-06-1511.17%7.1M63.3M346.63K
2026-05-2911.90%7.5M63.3M442.47K
2026-05-1512.00%7.6M63.3M459.17K
2026-04-3011.88%7.5M63.0M483.24K
2026-04-1512.19%7.7M63.0M549.06K
2026-03-3112.09%7.6M62.8M549.90K
2026-03-1312.74%8.0M62.8M534.56K
2026-02-2712.55%7.9M62.8M445.50K
2026-02-1312.54%7.7M61.6M441.18K
2026-01-3012.47%7.7M61.5M436.85K
2026-01-1511.75%7.3M62.1M391.92K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.052.200.005.5620.000.000.851-0.0650.002
call5.000.000.150.141.46732.000.000.278-0.0180.002
call7.500.000.750.003.0350.000.000.170-0.0290.002
call10.000.000.600.005.9400.000.000.343-0.0770.003
put2.500.000.750.007.5070.000.00-0.149-0.0650.002
put5.000.351.300.003.0740.000.00-0.722-0.0180.002
put7.502.503.900.005.3260.000.00-0.830-0.0280.002
put10.005.106.500.006.7810.000.00-0.857-0.0320.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-098-KCurrent report2026-11-06SEC
2026-10-06SCHEDULE 13GSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-05-214/A2026-05-18SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-06SCHEDULE 13G/ASEC
2026-04-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-134Statement of changes in beneficial ownership of securities2026-03-11SEC
2026-03-0510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-058-KCurrent report2026-03-05SEC
2026-02-09SCHEDULE 13GSEC
2026-02-034Statement of changes in beneficial ownership of securities2026-01-31SEC
2026-02-034Statement of changes in beneficial ownership of securities2026-01-31SEC
2026-02-034Statement of changes in beneficial ownership of securities2026-01-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.00%
BlackRock, Inc.10.90%
BML Capital Management, LLC8.42%
TANG CAPITAL MANAGEMENT LLC6.02%
VANGUARD CAPITAL MANAGEMENT LLC3.70%
ACADIAN ASSET MANAGEMENT LLC2.92%
Bain Capital Life Sciences Investors, LLC2.59%
GEODE CAPITAL MANAGEMENT, LLC2.38%
STATE STREET CORP2.06%
TWO SIGMA INVESTMENTS, LP1.88%

Funds

Fund% owned
Fidelity Growth Company Fund3.90%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.54%
iShares Russell 2000 ETF2.29%
Fidelity Growth Company K6 Fund1.52%
VANGUARD EXTENDED MARKET INDEX FUND1.08%
Fidelity Small Cap Index Fund0.96%
Fidelity Series Growth Company Fund0.92%
iShares Russell 2000 Value ETF0.84%
BlackRock Advantage Small Cap Core Fund0.76%
iShares Biotechnology ETF0.55%

OakChart. AVIR. Cached 15 minutes.